Dabigatran Etexilate
CORT125134-132
Phase 1 small_molecule completed
Quick answer
Dabigatran Etexilate for Cushing Syndrome is a Phase 1 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CORCEPT THERAPEUTICS INC
- Indication
- Cushing Syndrome
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed